Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 2

Status

Completed 4Unknown 2Recruiting 2Withdrawn 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Endocrine 1

Conditions

Pituitary Neoplasms 1Haloperidol 1Growth Hormone-Secreting Pituitary Adenoma 1Acromegaly 1

Interventions

Cisplatin 130Radiotherapy 94Carboplatin 85Paclitaxel 78Fluorouracil 78Cyclophosphamide 77Gemcitabine 72Capecitabine 66Docetaxel 65Doxorubicin 60Oxaliplatin 59Etoposide 57Leucovorin 49Vincristine 47Chemotherapy, Adjuvant 42Cytarabine 38Dexamethasone 35Drug Therapy 33Bevacizumab 30Epirubicin 29Neoadjuvant Therapy 28Pemetrexed 27Tamoxifen 25Prednisone 24Irinotecan 24Rituximab 21Methotrexate 21Radiotherapy, Intensity-Modulated 19apatinib 18Vinorelbine 18

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Unknown × Solutions × Clear all
NCT04833023 2024-04-12

HALO Trial: Haloperidol vs Olanzapine in Hyperactive Delirium in Palliative Care Patients; A Multi-Centre, Randomised-Controlled Trial

Tan Tock Seng Hospital

Phase 3 Unknown
72 enrolled

Haloperidol

NCT03439709 2018-03-01

MERGE

Samsung Medical Center

Phase 3 Unknown
90 enrolled
Endocrine

Acromegaly, Pituitary Neoplasms, Growth Hormone-Secreting Pituitary Adenoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡